Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Algeria has been experiencing a steady growth in recent years.
Customer preferences: Algeria's population is aging, and with that comes an increase in chronic diseases, such as organ transplants, autoimmune diseases, and cancer. These diseases require the use of immunosuppressants, which has led to an increase in demand for these drugs. Additionally, the country has a high prevalence of hepatitis C, which is a leading cause of liver transplants, further contributing to the demand for immunosuppressants.
Trends in the market: The market for immunosuppressants in Algeria has been growing due to the increasing number of patients requiring these drugs. The market is dominated by generic drugs, which are more affordable for patients. However, there has been a recent trend towards the use of branded drugs, which are perceived to be of higher quality and more effective. This trend is driven by the increasing awareness among patients and healthcare professionals about the importance of quality and efficacy in treating chronic diseases.
Local special circumstances: Algeria has a public healthcare system that provides free healthcare to its citizens. However, the system is underfunded and understaffed, leading to long waiting times and a shortage of drugs in some areas. This has led to a rise in private healthcare providers, who are able to provide better quality care and a wider range of drugs, including branded immunosuppressants. Additionally, Algeria has a large pharmaceutical industry, which produces generic drugs at a lower cost than imported drugs.
Underlying macroeconomic factors: Algeria's economy is heavily dependent on oil and gas exports, which account for over 90% of its exports. The country has been experiencing an economic downturn in recent years due to the decline in oil prices, leading to a decrease in government spending on healthcare. This has led to a shortage of drugs in some areas and a rise in prices of imported drugs. However, the government has been increasing its investment in the healthcare sector, which is expected to drive the growth of the immunosuppressants market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
